260 related articles for article (PubMed ID: 33917026)
1. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
Zhang L; Ramesh P; Steinmetz M; Medema JP
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
[TBL] [Abstract][Full Text] [Related]
2. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
3. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
[TBL] [Abstract][Full Text] [Related]
4. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
[TBL] [Abstract][Full Text] [Related]
5. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
6. BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy.
Ramesh P; Medema JP
Apoptosis; 2020 Jun; 25(5-6):305-320. PubMed ID: 32335811
[TBL] [Abstract][Full Text] [Related]
7. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
8. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
[TBL] [Abstract][Full Text] [Related]
9. Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.
Vera MB; Morris-Hanon O; Nogueiras GI; Ripari LB; Esquivel MI; Perez-Castro C; Romorini L; Sevlever GE; Scassa ME; Videla-Richardson GA
Sci Rep; 2022 Oct; 12(1):17729. PubMed ID: 36273072
[TBL] [Abstract][Full Text] [Related]
10. Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-X
Oh Y; Jung HR; Min S; Kang J; Jang D; Shin S; Kim J; Lee SE; Sung CO; Lee WS; Lee C; Jeong EM; Cho SY
Cancer Lett; 2021 Jan; 497():123-136. PubMed ID: 33068701
[TBL] [Abstract][Full Text] [Related]
11. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma.
Mukherjee N; Strosnider A; Vagher B; Lambert KA; Slaven S; Robinson WA; Amato CM; Couts KL; Bemis JGT; Turner JA; Norris DA; Shellman YG
Cell Death Dis; 2018 Sep; 9(9):907. PubMed ID: 30185782
[TBL] [Abstract][Full Text] [Related]
12. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
13. Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment.
Abdul Rahman SF; Xiang Lian BS; Mohana-Kumaran N
Future Oncol; 2020 Oct; 16(28):2235-2249. PubMed ID: 32715755
[TBL] [Abstract][Full Text] [Related]
14. By reducing global mRNA translation in several ways, 2-deoxyglucose lowers MCL-1 protein and sensitizes hemopoietic tumor cells to BH3 mimetic ABT737.
Tailler M; Lindqvist LM; Gibson L; Adams JM
Cell Death Differ; 2019 Sep; 26(9):1766-1781. PubMed ID: 30538285
[TBL] [Abstract][Full Text] [Related]
15. Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.
Modi V; Sankararamakrishnan R
J Mol Graph Model; 2017 May; 73():115-128. PubMed ID: 28279820
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
17. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
Surman DR; Xu Y; Lee MJ; Trepel J; Brown K; Ramineni M; Splawn TG; Diggs LP; Hodges HC; Davis JL; Lee HS; Burt BM; Ripley RT
Mol Cancer Ther; 2021 Aug; 20(8):1469-1480. PubMed ID: 34088830
[TBL] [Abstract][Full Text] [Related]
19. The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
Zaanan A; Okamoto K; Kawakami H; Khazaie K; Huang S; Sinicrope FA
J Biol Chem; 2015 Sep; 290(39):23838-49. PubMed ID: 26245900
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
